• English
  • 简体中文
  • 繁體中文
  • Tiếng Việt
  • ไทย
  • Indonesia
Subscribe
Real-time News
On January 14th, Goldman Sachs issued a research report giving China Biopharmaceutical (01177.HK) a "Buy" rating with a target price of HK$6.19. This target price is based on a 12-month sum-of-the-parts valuation method, where the innovative drug pipeline is valued at RMB 69.3 billion using a discounted cash flow method, while the generic drug business is valued at RMB 46.8 billion based on a P/E ratio of 12 and a five-year CAGR of 5%. China Biopharmaceutical announced the acquisition of 100% equity in Hergia for a total price of RMB 1.2 billion, with approximately RMB 1.1 billion paid in cash and the remaining RMB 97 million to be paid in installments through new shares. Hergia is a clinical-stage biotechnology company focusing on siRNA technology, currently possessing four clinical-stage projects targeting Lp(a), ApoC3, THRbeta, and HBV, and more than 10 preclinical candidate products. This is the third acquisition by China Biopharmaceutical in two years. Goldman Sachs believes that as siRNA technology gradually becomes an important innovative model for the treatment of chronic diseases, this acquisition will strengthen China Biopharmaceuticals R&D pipeline in the fields of cardiovascular, metabolic and liver diseases, and create synergies with its existing products.According to the General Administration of Customs, China imported 9,951.6 tons of rare earths in December, compared with 5,221 tons in November.According to the General Administration of Customs, China imported 101,062 tons of rare earths from January to December.According to the General Administration of Customs, China imported 13.448 million tons of natural gas in December, compared with 11.947 million tons in November.According to the General Administration of Customs, China imported 127.865 million tons of natural gas from January to December.

Due to increased demand for its fresh products, Lululemon raises its annual forecasts

Haiden Holmes

Sep 02, 2022 11:16

2.png


As affluent clients purchase the company's new belt bags, golf, and tennis equipment, Lululemon Athletica Inc. raised its annual profit and revenue forecasts on Thursday, propelling its stock price 10% higher in extended trading.


Due to the money they saved during the lockdowns, consumers with higher earnings have mostly shrugged off the impacts of inflation in order to purchase non-essential products like clothing and handbags.


On the earnings call, Lululemon's CEO Calvin McDonald indicated that there has been no major shift in client purchasing habits.


In order to sustain its athleisure-driven sales growth and outperform competitors Athleta and Sweaty Betty, the company has introduced new styles, expanded into footwear categories, and introduced a men's line.


Analysts have also observed that discounts at Lululemon, which has a relatively new inventory, have climbed only marginally over the past few weeks, although its competitors have dropped prices dramatically to boost overall sales and get rid of out-of-style items.


McDonald remarked, "Lululemon remains predominantly a full-price business, and we do not intend to change our promotional cadence or markdown strategy."


In the coming weeks, Lululemon aims to release a variety of products, including footwear and bags, as Chinese manufacturers increase output in response to this year's easing of COVID-19 limitations.


Earnings and sales projections for 2022 have been increased beyond market estimates.


It increased its adjusted per-share earnings forecast from $9.35 to $9.50 to between $9.75 and $9.90, as well as its net sales projection from $7.61 billion to $7.71 billion to between $7.87 billion and $7.94 billion.


The second quarter net revenue climbed by 29% to $1.87 billion, above expectations of $1.77 billion.


The company's adjusted earnings per share of $2.20 beat forecasts of $1.87, according to Refinitiv data.